Engaging Thought Leadership
Over 75 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Discovery US 2024
19 - 20 November 2024 | Boston, MA
Connecting experts in biology & chemistry to advance small molecule drug discovery
Discovery US 2024
Meet Our Expert Speakers
The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery US 2023: 01 - 02 November 2023, Cambridge, USA
BanuPriya Sridharan
Associate Director,
GSK
Beth Hoffman
Chief Executive Officer,
Origami Therapeutics
Dane Corneil
Director of AI Science,
Benevolent AI
Eric Martin
Director,
Novartis
Joe Franklin
Vice President,
Anagenex
Lauren Goodrich
VP, Therapeutic Discovery,
Nimble Therapeutics
Nils Hansen
Chief Executive Officer,
Vipergen
Thomas Nittoli
Senior Director,
Regeneron
All Speakers
Aaron Frank
Head of Computational Chemistry,
Arrakis Therapeutics
Abhinav Sharma
Translational Human Models Lead Engineer, Discovery Immunology,
AbbVie
Amir Nikooie
Director,
Eli Lilly
Andrew Doran
Principal Scientist, Automation,
Anagenex
Angel Guzman-Perez
Executive Vice President, Head of Chemistry,
Scorpion Therapeutics
Dave Mauger
Director of Data Science,
Arrakis Therapeutics
Elliott Nickbarg
principal scientist,
merck
Emmanuel Bengio
Senior Machine Learning Scientist,
Recursion Pharmaceuticals
Eric Miele
Associate Director Proteomics,
AstraZeneca
Esther Lee
Associate Director, Medicinal Chemistry,
AstraZeneca
Glenn Kazo
Chief Business Officer,
ARIZ Precision Medicine
Govinda Bhisetti
Vice President,
Cellarity
Hasan Khan
Senior Scientist II,
AbbVie
Hongwu Wang
Principal Scientist,
Merck US
India Ott
Scientist,
AstraZeneca
Istvan Enyedy
Senior Principal Scientist,
UCB
James Hickman
Professor of NanoScience Technology,
University of Central Florida
Jason Ekert
Heas translational biology,
ucb
Jeannie Lee
Professor of Genetics,
Brigham and Women's Hospital
Jeff Messer
Director Analytics,
GSK
John Santa Maria
Associate Director of Cheminformatics,
FogPharma
Justyna Sikorska
Associate Principal Scientist,
Merck US
Kevin Robbins
Associate Principal Scientist,
AstraZeneca
Kingsley Appiah
Director, In Vitro Pharmacology & HTS,
Dewpoint Therapeutics
Kumar Suresh
Vice President R&D,
Progenra Inc.
Lee Herman
Director Computational Chemistry,
Sunovion Pharmaceuticals
Lucas Mastromatteo
Data Analyst,
GSK
Mark Murcko
Principal,
Dewpoint Therapeutics
Martin Redhead
Executive Director Primary Pharmacology,
Exscientia
.jpg?length=600&name=d7cb1243-6a15-4eca-b1df-41e7c0c7d5c2-2-11764368speaker_photo-JAU_0372-(2).jpg)
Matthew Pharris
Senior Scientist,
UCB
Maximilian Schuier
Senior Global Medical Affairs Leader Neuropsychiatry,
Janssen
Mike Schopperle
CEO,
CureMeta
Paul Scola
Scientist,
Bristol Myers squobb
Rajeswari Basu
Post Doctoral Scientist,
Stony Brook University
Ralph Mazitschek
Professor,
Brigham and Women's Hospital
Shahar Keinan
Chief Executive Officer,
POLARISqb
Shaun McLoughlin
Senior Scientist III,
AbbVie
Sina Mohammadi
Principal Scientist,
Merck US
Stefan Peukert
Associate Director,
Novartis
Timothy Smith
Associate Director of Sales,
bit.bio
Tobias Raabe
Research Assistant Professor,
University of Pennsylvania
Tomasz Cierpicki
Professor,
University of Michigan
Xiang Chen
Associate Member,
St Jude Children's Research Hospital
Yuan Wang
Head, Research Analytics,
UCB
Yuxin Liang
Senior Principal Scientific Manager, The NGS Lab,
Genentech
Meet Our Esteemed Sponsors
Silver Sponsors
Network & Programme Sponsors
Sponsors of Discovery US 2023 included
Admescope/Symeres
Network & Programme Sponsor
Admescope is a preclinical contract research organization (CRO) providing tailor-made ADME-Tox (Absorption, Distribution, Metabolism, Excretion and Toxicity) services for drug discovery and development companies. Our unique expertise lies in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis, where we stand out with our innovative approach combined with the latest technology. We are committed to working closely with our customers throughout the whole study process. All studies include comprehensive study planning, tailoring the assay according to the compound(s) and interpretation of the results with recommendations for the future. Our careful individualistic approach enables us to provide high scientific and technical data quality that our customers can truly rely on in their decision making. Admescope is part of the Symeres family, the leading mid-sized transatlantic CRO with over 600 scientists in Europe and the USA, offering early stage hit finding all the way to the delivery of your early clinical drug substance API. We are large enough to matter and small enough to care.
Immunocure Discovery Solutions
Exhibition and Tech Demo Sponsor
Immunocure is a preclinical drug discovery CRO, that leverages an in-house generative AI-based discovery platform – AxDrug® integrated with HPC-powered computational chemistry tools and synthetic chemistry lab to create best-in-class lead candidates for our clients.
MIMETAS
Network & Programme Sponsor
MIMETAS is a global leader in disease modeling using Organ-on-a-Chip technologies. Founded in 2013 in Leiden, the Netherlands, MIMETAS strives to contribute to ground-breaking therapies with their screenable, physiologically relevant human disease models. MIMETAS believes that phenotypic tissue-and disease modeling is at the heart of 21st-century therapy development. By combining technological strengths and expertise, MIMETAS establishes strong drug development partnerships with and offers services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases.
Nuclera
Exhibition and Tech Demo Sponsor
Nuclera is driven by the mission to better human health by increasing accessibility to proteins. We are committed to providing rapid access to high-quality, soluble, active proteins at the benchtop allowing researchers to accelerate their protein projects, enabling faster success. Using Nuclera’s eProtein Discovery™ system scientists can automate construct screening to inform off-platform protein scale up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
Vivlion GmbH
Network & Programme Sponsor
Vivlion GmbH is a gene editing company based in Germany providing its disruptive PRCISR™ CRISPR platform to pharma and biotech companies worldwide. PRCISR™ CRISPR is based on the proprietary PCR-free 3Cs technology developed at Goethe University Frankfurt, Germany, and includes next-generation gene editing solutions and advanced gRNA libraries enabling highly efficient and combinatorial CRISPR screens. In addition, PRCISR™ CRISPR includes experimental design and bioinformatic solutions. https://vivlion.com/products-and-services/
XtalPi
Network & Programme Sponsor
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2014 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
.png)
Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments
Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.
Newcells Products and Services
From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments
Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.
Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre
Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.
AI-driven High Throughput Screening for Targeted Drug Discovery
Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.
Post-Event Proceedings – Discovery Europe 2023
Concise and insightful summaries of presentations delivered by prominent thought leaders at Discovery Europe 2023.